Immunoprecise Antibodies (IPA)

• Market cap: $11.9M
• 1 day: -7.42%
• 5 days: -5.40%
• 1 month: -23.80%
• 3 months: -57.14%
• 6 months: -64.83%
• Year to date: -75.79%
• 1 year: -70.40%
• 5 years: -97.42%
• 10 years: -97.42%

About: ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.

Employees: 101

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0.46% more ownership

Funds ownership: 6.33% [Q2] → 6.8% (+0.46%) [Q3]

5% less funds holding

Funds holding: 19 [Q2] → 18 (-1) [Q3]

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

28% less capital invested

Capital invested by funds: $1.69M [Q2] → $1.21M (-$476K) [Q3]

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $9 2,087% upside
• Avg. target: $9 2,087% upside
• High target: $9 2,087% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Swayampakula Ramakanth 32% 1-year accuracy 46 / 142 met price target

2,087% upside $9

Buy Reiterated

17 Sept 2024